Garonne, France

Peter E Keane


Average Co-Inventor Count = 3.6

ph-index = 2

Forward Citations = 40(Granted Patents)


Location History:

  • Toulouse, FR (1989)
  • Garonne, FR (1991)
  • Portet-Sur-Garonne, FR (1991)

Company Filing History:


Years Active: 1989-1991

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Peter E Keane: Innovator in Pharmaceutical Compounds

Introduction

Peter E Keane is a notable inventor based in Garonne, France. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that have various medicinal applications. With a total of 3 patents, his work focuses on innovative solutions for treating cardiovascular diseases, allergies, and anxiety.

Latest Patents

Keane's latest patents include the development of 4-amino quinolines and naphthyridines, which are represented by complex chemical formulas. These compounds are designed for use as medicines, showcasing their potential in the prevention and treatment of cardiovascular diseases, as well as their effectiveness as anti-allergic drugs. Additionally, he has worked on derivatives of 4-amino 3-carboxy naphthyridines, which possess properties that affect the nervous system.

Career Highlights

Peter E Keane is associated with Sanofi, a leading global healthcare company. His work at Sanofi has allowed him to focus on innovative pharmaceutical research and development. His contributions have been instrumental in advancing medical treatments and improving patient outcomes.

Collaborations

Throughout his career, Keane has collaborated with esteemed colleagues such as Etienne Mendes and Jean-Claude Vernieres. These partnerships have fostered a collaborative environment that enhances the innovation process and leads to groundbreaking discoveries in the pharmaceutical field.

Conclusion

Peter E Keane's work exemplifies the impact of innovation in medicine. His patents and collaborations highlight his commitment to advancing healthcare solutions. His contributions continue to shape the future of pharmaceutical research and development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…